In this context, we conducted a multinational, retrospective analysis to evaluate the real‐world outcomes of gilteritinib administered as third‐line or beyond therapy in patients with R/R FLT3‐mutated AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.